ARK Invest's position in SCTX, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 1,522,449 | $25.9M | 1.31% | #24 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-12 | ARKG | Buy | Added | 39,090 | $664K |
| 2026-11-11 | ARKG | Buy | Added | 7,942 | $134K |
| 2026-11-09 | ARKG | Buy | Added | 5,660 | $94K |
| 2026-11-06 | ARKG | Buy | Added | 37,246 | $585K |
| 2026-11-05 | ARKG | Buy | Added | 61,828 | $957K |
| 2026-11-04 | ARKG | Buy | Added | 6,175 | $104K |
| 2026-11-03 | ARKG | Buy | Added | 7,987 | $129K |
| 2026-11-02 | ARKG | Buy | Added | 10,525 | $164K |
| 2026-10-23 | ARKG | Buy | Added | 22,479 | $346K |
| 2026-10-22 | ARKG | Buy | Added | 99,254 | $1.8M |
| 2026-10-21 | ARKG | Buy | Added | 199,698 | $3.9M |
| 2026-10-20 | ARKG | Buy | Added | 10,832 | $215K |
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based…
See SCTX's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open SCTX on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.